This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, eHealth) (343) Health Services Research (413) Kinesiology (9) Portable and Mobile Technologies for Rehabilitation (142) Mobile Health (mhealth) (2777) mHealth for Rehabilitation (236)

Published on in Vol 12 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/44832, first published .
Evaluation and Management of Dyspnea in Hypermobile Ehlers-Danlos Syndrome and Generalized Hypermobility Spectrum Disorder: Protocol for a Pilot and Feasibility Randomized Controlled Trial

Evaluation and Management of Dyspnea in Hypermobile Ehlers-Danlos Syndrome and Generalized Hypermobility Spectrum Disorder: Protocol for a Pilot and Feasibility Randomized Controlled Trial

Evaluation and Management of Dyspnea in Hypermobile Ehlers-Danlos Syndrome and Generalized Hypermobility Spectrum Disorder: Protocol for a Pilot and Feasibility Randomized Controlled Trial

Authors of this article:

Dmitry Rozenberg1, 2, 3 Author Orcid Image ;   Noor Al Kaabi2, 3, 4 Author Orcid Image ;   Encarna Camacho Perez3, 4 Author Orcid Image ;   Sahar Nourouzpour4 Author Orcid Image ;   Laura Lopez-Hernandez3 Author Orcid Image ;   Laura McGillis3 Author Orcid Image ;   Ewan Goligher2, 4, 5 Author Orcid Image ;   W Darlene Reid6, 7 Author Orcid Image ;   Chung-Wai Chow2, 4 Author Orcid Image ;   Clodagh M Ryan6 Author Orcid Image ;   Dinesh Kumbhare2, 6, 8 Author Orcid Image ;   Ella Huszti9 Author Orcid Image ;   Kateri Champagne10 Author Orcid Image ;   Satish Raj11 Author Orcid Image ;   Susanna Mak2, 12 Author Orcid Image ;   Daniel Santa Mina3, 8, 13 Author Orcid Image ;   Hance Clarke2, 3, 13 Author Orcid Image ;   Nimish Mittal2, 3, 6, 8, 13 Author Orcid Image
Article Authors Cited by Tweetations (13) Metrics

    Protocol

    1Respirology and Lung Transplantation, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada

    2Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada

    3GoodHope Ehlers-Danlos Syndrome Clinic, University Health Network, Toronto, ON, Canada

    4Respirology, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada

    5Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada

    6KITE—Toronto Rehab, University Health Network, Toronto, ON, Canada

    7Physical Therapy, University of Toronto, Toronto, ON, Canada

    8Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON, Canada

    9Biostatistics Research Unit, University Health Network, Toronto, ON, Canada

    10Institut de Médecine du Sommeil, Montreal, QC, Canada

    11Department of Cardiac Sciences, Cumming School of Medicine, Calgary, AB, Canada

    12Department of Cardiology, Mount Sinai Hospital, Toronto, ON, Canada

    13Department of Anesthesia and Pain Management, University Health Network, Toronto, ON, Canada

    *these authors contributed equally

    Corresponding Author:

    Dmitry Rozenberg, MD, PhD

    Respirology and Lung Transplantation

    Toronto General Hospital Research Institute

    University Health Network

    200 Elizabeth Street

    Toronto, ON, M4G 2C4

    Canada

    Phone: 1 416 340 4800 ext 7358

    Email: dmitry.rozenberg@uhn.ca


    Background: Dyspnea is a prevalent symptom in individuals with hypermobile Ehlers-Danlos Syndrome (hEDS) and generalized hypermobility spectrum disorder (G-HSD), yet its contributors have not been identified. One known contributor to dyspnea is respiratory muscle weakness. The feasibility and effectiveness of inspiratory muscle training (IMT) in combination with standard-of-care rehabilitation (aerobic, resistance, neuromuscular stabilization, and balance and proprioception exercises) in improving respiratory muscle strength and patient-reported outcomes in patients with hEDS or G-HSD have not been evaluated.

    Objective: This study aims to evaluate dyspnea, respiratory muscle strength, and patient-reported outcome measures (PROMs) in hEDS or G-HSD compared with healthy controls and to assess the feasibility of a randomized controlled trial of IMT and standard-of-care rehabilitation for improving respiratory muscle strength, exercise capacity, and PROMs compared with standard-of-care rehabilitation in hEDS and G-HSD.

    Methods: The study will include 34 participants with hEDS or G-HSD and 17 healthy, age- and sex-matched controls to compare respiratory muscle structure and function and PROMs. After baseline assessments, participants with hEDS or G-HSD will be randomized into the intervention group and provided IMT combined with Ehlers-Danlos Syndrome standard-of-care rehabilitation or into the usual care group, and provided only standard-of-care rehabilitation for 8 weeks. The intervention group will be prescribed IMT in their home environment using the POWERbreathe K5 IMT device (POWERbreathe International Ltd). IMT will comprise 2 daily sessions of 30 breaths for 5 days per week, with IMT progressing from 20% to 60% of the baseline maximal inspiratory pressure (MIP) over an 8-week period. Feasibility will be assessed through rates of recruitment, attrition, adherence, adverse events, and participant satisfaction. The primary pilot outcome is MIP change over an 8-week period in hEDS or G-HSD. Secondary outcomes will include the evaluation of dyspnea using Medical Research Council Scale and 18-point qualitative dyspnea descriptors; diaphragmatic thickening fraction using ultrasound; respiratory muscle endurance; pulmonary function; prefrontal cortical activity using functional near-infrared spectroscopy; aerobic capacity during cardiopulmonary exercise testing; quality of life using Short Form-36; and scores from the Depression, Anxiety, and Stress scale-21. These measures will also be performed once in healthy controls to compare normative values. Multivariable regression will be used to assess the contributors to dyspnea. Paired 2-tailed t tests will be used to assess the changes in MIP and secondary measures after 8 weeks of IMT.

    Results: Study recruitment began in August 2021 and, with several disruptions owing to COVID-19, is expected to be completed by December 2023.

    Conclusions: This study will provide a better understanding of the factors associated with dyspnea and the feasibility and effectiveness of IMT combined with standard-of-care rehabilitation. IMT may be a novel therapeutic strategy for improving respiratory muscle function and patient-reported outcomes in individuals with hEDS or G-HSD.

    Trial Registration: ClinicalTrials.gov NCT04972565; https://clinicaltrials.gov/ct2/show/NCT04972565

    International Registered Report Identifier (IRRID): DERR1-10.2196/44832

    JMIR Res Protoc 2023;12:e44832

    doi:10.2196/44832

    Keywords

    Ehlers-Danlos Syndrome; generalized hypermobility spectrum disorders; inspiratory muscle training; rehabilitation; exercise; mobile phone 


    Background

    Ehlers-Danlos Syndrome (EDS) is a group of hereditary connective tissue disorders characterized by multisystem manifestations involving musculoskeletal and nonmusculoskeletal domains [1]. Currently, the International Classification of EDS and related disorders includes 14 subtypes based on a set of clinical criteria, with the most common subtype being hypermobile EDS (hEDS), which comprises 80% to 90% of EDS cases [1-3]. Patients who present with symptomatic generalized joint hypermobility and chronic pain but do not meet the International 2017 classification criteria are classified as having generalized hypermobility spectrum disorder (G-HSD) [3]. The clinical manifestations of the disease vary according to the EDS subtype, and our understanding of this disorder has evolved to recognize multisystem manifestations beyond the musculoskeletal system, including gastrointestinal, neurological, cardiovascular, and respiratory involvement [1]. These manifestations arise from abnormal collagen or proteins that bind collagen that affect the connective tissue throughout the body [1]. Given the multisystem nature of hEDS and G-HSD, several symptoms such as pain and fatigue may contribute to reduced health-related quality of life (HRQL), physical deconditioning, anxiety, and depression [4-8].

    Respiratory Manifestations in EDS and G-HSD

    Our research group and others have recently highlighted that respiratory manifestations are common in hEDS and G-HSD and include, but are not limited to, dyspnea, cough, asthma, and respiratory muscle weakness [2,9]. The collagen abnormalities lead to impairments throughout the respiratory system, which may contribute to the respiratory abnormalities observed in this population [2,10]. In individuals with hEDS, the prevalence of dyspnea is estimated to be approximately 50% [11]. Dyspnea has been described in a few studies on individuals with G-HSD, but its prevalence and determinants have not been well characterized [12]. A study reported that up to 26% of the patients with G-HSD presented with cardiorespiratory manifestations such as dyspnea, palpitations, and chest pain, which were commonly attributed to autonomic dysfunction [13].

    Respiratory symptoms in EDS and G-HSD have also been associated with worse outcomes such as lower physical activity levels and function. Individuals with EDS or G-HSD experienced increased dyspnea while walking on a flat level compared with healthy controls [12]. Furthermore, a study investigating physical activity levels between patients with hEDS or G-HSD with autonomic dysfunction and those without autonomic dysfunction observed that autonomic dysfunction was associated with exercise intolerance, which is often attributed to increased symptoms of dyspnea and chest pain [14]. Postural orthostatic tachycardia syndrome, a more severe form of autonomic dysfunction, has also been observed to be associated with dyspnea, chest pain, and impairments in HRQL [15,16]. Thus, respiratory manifestations in individuals with hEDS or G-HSD have important consequences on exercise tolerance, HRQL, and functional abilities.

    Contributors to Dyspnea in hEDS and G-HSD

    Functional impairments in respiratory muscle weakness occur in >75% of individuals with hEDS and can result in dyspnea and a restrictive pattern of ventilation [11]. The diaphragm is the main respiratory muscle, and alterations in collagen can lead to impairments in the respiratory muscle structure and function [17]. Respiratory muscle weakness has also been associated with lower vital capacity, which may contribute to dyspnea [18,19]. Thus, strengthening the respiratory muscles through modalities such as inspiratory muscle training (IMT) may improve dyspnea and pulmonary function [20].

    Some individuals with hEDS or G-HSD have been observed to have chest wall deformities and increased rates of asthmatic symptoms, which can contribute to dyspnea and peripheral airway abnormalities [12,21,22]. There is also an increased tendency for dynamic airway collapse despite normal chest imaging, which highlights altered lung mechanics, including airway pressures and lung volumes [12]. Furthermore, deconditioning has been described as a contributor to low physical activity levels in the population with EDS or G-HSD as a consequence of increased joint laxity, pain, and peripheral muscle weakness [23]. Physical deconditioning may further exacerbate dyspnea and contribute to low exercise tolerance [23]. In conditions such as chronic obstructive pulmonary disease (COPD), cortical neural activity in the prefrontal cortex (PFC) has been shown to be associated with dyspnea and exercise intolerance and may be another contributor to dyspnea in hEDS or G-HSD [24,25]. Modalities such as functional near-infrared spectroscopy (fNIRS) have been used to assess PFC activity in individuals experiencing dyspnea during exercise testing [24]. Taken together, respiratory muscle weakness, peripheral airway changes, physical deconditioning, and autonomic dysfunction may contribute to the multifactorial nature of dyspnea in hEDS or G-HSD. These factors can be evaluated clinically and may help us understand the mechanisms that contribute to dyspnea and, importantly, tailor effective respiratory management strategies.

    IMT and Standard-of-Care Rehabilitation

    IMT has been established as an effective intervention for improving respiratory muscle structure and function in populations with chronic lung diseases [26,27]. A study observed that among 104 individuals with hEDS, 80 (77%) individuals had respiratory muscle weakness [11]. After 6 weeks of IMT, respiratory muscle strength measured with sniff nasal inspiratory pressure improved by 20% (pre-IMT intervention: mean 41, SD 17 cm H2O vs post-IMT measurement: mean 49, SD 18 cm H2O; P<.001) in patients with hEDS. Furthermore, the 6-minute walk distance improved by 13% (pre-IMT measurement: mean 455, SD 107 m vs post-IMT measurement: mean 515, SD 127 m; P=.003) along with forced expiratory volume in 1 second by 10% (pre-IMT measurement: mean 94%, SD 14% vs post-IMT measurement: mean 103%, SD 11%; P=.01). Thus, IMT may be an effective intervention for improving respiratory muscle strength, lung function, and exercise capacity in patients with hEDS or G-HSD.

    Physical rehabilitation involving whole-body exercises such as aerobic and strength training has been shown to improve dyspnea in healthy populations and populations with chronic lung diseases such as COPD and idiopathic pulmonary fibrosis [28-31]. In a meta-analysis of 14 randomized controlled trials (RCTs), resistance training and endurance training were associated with improved dyspnea tolerance during exercise training, along with resting dyspnea levels, in patients with COPD [30]. This is often attributed to improved physical fitness owing to exercise training, which increases the efficiency of the muscles and decreases the level of ventilatory demand [30]. Unlike other populations, research on the effects of exercise training on individuals with hEDS or G-HSD is in its early stages, with only 5 RCTs performed in this area to date [32]. Following rehabilitation, in patients with hEDS or G-HSD, improvements have been observed in exercise capacity, muscle strength, mood, HRQL, and performance of daily activities [32].

    Although the IMT RCT highlighted the safety and feasibility of IMT in hEDS, the study did not evaluate the mechanisms of dyspnea or assess diaphragm structure and function [11]. Furthermore, physical activity and other concurrent training, which may provide synergistic beneficial effects on respiratory symptoms and exercise capacity, were not considered. Several studies on chronic lung disease have demonstrated that IMT in combination with whole-body exercises, such as aerobic exercise, offers synergistic benefits on respiratory muscle strength and endurance and exercise capacity in comparison with whole-body exercises alone [23,33,34]. IMT alone has been shown to be an effective intervention in populations with asthma, populations with COPD, and populations with interstitial lung disease for improving maximal inspiratory pressure (MIP), respiratory muscle endurance, and diaphragm function [26,27,35] and thus may be an effective strategy in the population with hEDS or G-HSD.

    The efficacy of both IMT and standard-of-care rehabilitation in ameliorating dyspnea and improving aerobic capacity and respiratory muscle structure and function in the population with hEDS or G-HSD has not been investigated to date. It is also unclear whether IMT in combination with standard-of-care rehabilitation is a feasible intervention, specifically for the population with hEDS or G-HSD, given the increased comorbidities. Furthermore, the efficacy of IMT has only been evaluated in hEDS and yet to be studied in G-HSD. This study aims to address these gaps.

    Study Aims

    The aims of this study are (1) to compare respiratory muscle strength and patient-reported outcome measures (PROMs) between individuals with hEDS or G-HSD and healthy, age- and sex-matched controls, as well as evaluate the main contributors to dyspnea in individuals with hEDS or G-HSD, and (2) to assess the feasibility of an RCT of IMT and standard-of-care rehabilitation (aerobic, resistance, neuromuscular stabilization, and balance and proprioception exercises) for improving respiratory muscle strength, exercise capacity, and PROMs compared with standard-of-care rehabilitation in hEDS or G-HSD.

    Hypotheses

    We hypothesize that (1) individuals with hEDS or G-HSD will have lower respiratory muscle strength, higher peripheral airway resistance, lower HRQL, and higher anxiety and depression levels than age- and sex-matched healthy controls and that (2) the delivery of IMT and standard-of-care rehabilitation will be feasible and result in a significant improvement in respiratory muscle strength (MIP) over an 8-week period.


    Study Design

    Participants with hEDS or G-HSD will complete assessments at baseline (T0; Table 1) and will be randomized into the intervention arm (IMT and standard-of-care rehabilitation) or usual care group (standard-of-care rehabilitation). The standard-of-care rehabilitation at the GoodHope EDS Clinic at Toronto General Hospital comprises active exercise training involving aerobic, resistance, neuromuscular stabilization, and balance and proprioception exercises, and is a part of the GoodHope Exercise and Rehabilitation Program (GEAR) [36].

    Age- and sex-matched healthy controls will undergo the same T0 assessments as those that the EDS and G-HSD intervention and usual care groups will undergo. The respiratory muscle structure and function, dyspnea, exercise capacity, and collected PROMs will be compared. Only the participants with hEDS or G-HSD (intervention and usual care groups) will repeat the T0 assessments after 8 weeks, as described in the subsequent section on assessments.

    Table 1. Summary of study measurements.
    MeasurementBaseline assessmentsa

    		Intervention and usual care groupsHealthy control group
    Dyspnea

    		Medical Research Council Dyspnea Scale✓✓

    		18-Point Qualitative Dyspnea Scale✓✓
    Pulmonary function tests

    		Oscillometry✓✓

    		Spirometry and lung volumes✓✓

    		Respiratory muscle enduranceb✓✓

    		Maximal respiratory pressures✓✓

    		Diaphragmatic measures✓✓
    PROMsc

    		Health-related quality of life: Short Form-36✓✓

    		Mood: Depression, Anxiety, and Stress scale✓✓

    		Physical activity volume: Godin Leisure-Time Exercise Questionnaire✓✓

    		Demographic questionnaire✓✓

    aAll baseline measures will be repeated after 8 weeks for the participants with hypermobile Ehlers-Danlos Syndrome or generalized hypermobility spectrum disorder.

    bRespiratory muscle endurance will be repeated at 4 weeks.

    cPROM: patient-reported outcome measure.

    Ethics Approval

    Ethics approval has been obtained from the research ethics board at the University Health Network (ID: 20-6346.0) and University of Toronto (ID: 42667). The study has been registered at ClinicalTrial.gov (NCT04972565).

    Written informed consent will be obtained from all participants before the commencement of any research activities. The Standard Protocol Items: Recommendations for Interventional Trials, the CONSORT (Consolidated Standards of Reporting Trials) statement, and the Consensus on Exercise Reporting Template will be used [37-39]. Refer to Figure 1 for the CONSORT flow diagram.

    ‎
    Figure 1. CONSORT (Consolidated Standards of Reporting Trials) flow diagram with healthy controls. GEAR: GoodHope Exercise and Rehabilitation Program; G-HSD: generalized hypermobility spectrum disorder; hEDS: hypermobile Ehlers-Danlos Syndrome; IMT: inspiratory muscle training.

    Recruitment and Screening

    Participants with hEDS or G-HSD will be recruited from the GEAR program at Toronto General Hospital, which is a major teaching hospital in Toronto, Canada. The GEAR program evaluates approximately 12 new participants per month. Potential participants are screened for study eligibility by exercise professionals who are part of the GEAR program. The research team will confirm the eligibility criteria, discuss study participation, and obtain consent among interested participants. The study flow of participants is shown in Figure 1.

    Participants With hEDS or G-HSD

    The sample will comprise adult individuals (aged ≥18 years) diagnosed with hEDS or G-HSD by the EDS medical team at Toronto General Hospital based on the 2017 diagnostic criteria [3]. Participants will be included if they have started their participation in the GEAR program within 4 weeks.

    The following exclusion criteria will be applied:

    1. Diagnosis of other subtypes of EDS (eg, classical and vascular)
    2. Have a cardiac pacemaker, defibrillator, neuromuscular disease, severe autonomic dysfunction, or other cardiovascular manifestations limiting exercise or other exercise contraindications
    3. Recent respiratory infection (<1 month) or known diagnosis of obstructive or restrictive parenchymal disease
    4. History of pneumothorax, acute otitis media (fluid behind the eardrum), or rupture of tympanic membranes, given the risk owing to IMT
    5. Participation in formal exercise training or IMT program within the last 3 months
    6. Insufficient English fluency to provide informed consent or inability to follow study protocols
    7. Self-reported pregnancy
    8. No internet access for IMT or web-based assessments

    Healthy Controls

    Healthy adults (aged ≥18 years) will be age- and sex-matched with the participants with EDS and G-HSD. Individuals will be excluded from the study if they meet the following criteria:

    1. Diagnosis of a respiratory, cardiovascular, or musculoskeletal condition that may contribute to exercise limitation
    2. Presence of cardiac pacemaker or implantable defibrillator
    3. Insufficient English fluency to provide informed consent or inability to follow study protocols
    4. Self-reported pregnancy
    5. Active smoker (cigarettes or marijuana)

    Assessments

    At T0, the participants with hEDS and G-HSD will undergo pulmonary function tests (PFTs), cardiopulmonary exercise test (CPET) with fNIRS on the PFC, PROMs, and diaphragm ultrasound. The same assessments will be performed for healthy controls. Please refer to Table 1 for a detailed list of T0 measurements. At 4 weeks, respiratory muscle endurance assessment will be repeated for the participants with hEDS and G-HSD. All T0 assessments, including PFTs, CPET, PROMs, and respiratory muscle endurance assessment, will be repeated at 8 weeks for the participants with hEDS and G-HSD.

    The following tests will be used to assess the primary and secondary outcome measures in the PFT laboratory at Toronto General Hospital.

    Respiratory Parameters

    Assessment Using PFTs
    Spirometry and Lung Volumes

    Forced expiratory volume in 1 second, forced vital capacity, total lung capacity, and lung volumes (tidal volume, inspiratory capacity, expiratory reserve, and residual volumes) will be evaluated in accordance with the American Thoracic Society guidelines before CPET [40].

    Oscillometry

    This will be performed before other PFTs according to the European Respiratory Society Guidelines, as previously described [41,42]. Oscillometry provides detailed information regarding respiratory mechanics by measuring respiratory impedance, a complex sum of respiratory resistance, and reactance [43]. This technique uses sound waves to capture disturbances in airway resistance and can be a more sensitive marker of peripheral airway obstruction than spirometry [44,45]. Because it is performed during normal breathing, oscillometry is independent of effort and is not influenced by respiratory muscle strength. We will follow the quality assurance and control guidelines developed by our group using the tremoflo device (Thorasys) [46].

    Respiratory Muscle Strength

    MIP and maximal expiratory pressure will be evaluated using the American Thoracic Society standards. These measures will be repeated 3 times, and the highest value (cm H2O) that is 10% within the lower measures will be used [47,48].

    Respiratory Muscle Endurance

    The threshold loading device (Threshold IMT trainer [Philips]) [49] will be used to evaluate respiratory muscle endurance. We will assess the time that can be sustained at respiratory endurance at 30% of MIP obtained as part of the T0 measures after a brief familiarization session with the loading device. The maximum endurance that the threshold loading device can reach is 41 cm H2O. The endurance assessment will be repeated within 5 minutes if the participant stops the protocol early (<1 minute) because of severe coughing or lack of familiarity with the loading device. The maximum endurance that participants will be asked to perform is 15 minutes. Oxygen saturation will be concurrently monitored with pulse oximetry during the assessment.

    Diaphragm Ultrasound

    While the participant is in semirecumbent position, the research coordinator will place an ultrasound probe perpendicular to the chest wall in the 8th or 9th intercostal space between the anterior and midaxillary lines using a 5-13 MHz transducer (GE Logiq e Laptop Ultrasound System [GE Medical Systems]) [50]. Bright-mode ultrasound will be used to visualize the diaphragm, and motion-mode ultrasound will be used to assess the amplitude of the cranio-caudal diaphragmatic excursion during quiet and deep breathing. Diaphragm thickness will be measured as the distance between the leading edges of the diaphragmatic pleura and peritoneum at resting end expiration and after peak inspiration. Thickening fraction, an established marker of diaphragm strength, will be calculated as follows: ([diaphragm thickness at end expiration–diaphragm thickness at peak inspiration] divided by diaphragm thickness at end expiation) × 100 [50].

    Assessment Using CPET
    Overview

    Symptom-limited CPET will be performed on a cycle ergometer (Elema), with exhaled gas measurements captured breath by breath, as routinely applied in our PFT laboratory. Testing will start with 2 minutes of complete rest on the bike, followed by unloaded pedaling for 2 minutes, and then exercise intensity will be increased by 10 to 20 W per minute using a ramp protocol. Blood pressure, 12-lead electrocardiogram, and peripheral oxygen saturation will be continuously monitored. Inspiratory capacity, tidal volumes, and respiratory rate will be measured throughout the exercise to assess for any dynamic hyperinflation and ventilatory reserve. Heart rate (HR) response, peak aerobic capacity, oxygen pulse (measure of cardiac stroke volume), and minute ventilation (product of tidal volume and respiratory rate) will be collected throughout the exercise and up to 2 minutes after test completion with unloaded pedaling, with percent predicted values reported. HR recovery (difference between peak HR and HR 1 minute after exercise) and the chronotropic response index ([peak HR – resting HR × 100] / [220 – age] – [resting HR]) will be collected as a measure of autonomic function [51-53]. Chronotropic incompetence is the inability to decrease HR after exercise or the inability to reach 80% of the maximal age-predicted HR because of abnormal sympathetic activation [51]. Symptom intensity for breathing and leg discomfort with exercise will be measured at rest and every 3 minutes throughout the exercise using the Borg dyspnea [54] and leg fatigue scales [55]. The reasons for exercise cessation will be ascertained from the participants (ie, dyspnea, leg fatigue, both, or other). To ensure participant safety before CPET, 12-lead electrocardiograms will be performed for both the participants with hEDS or G-HSD and healthy controls.

    Assessment Using fNIRS

    fNIRS is a noninvasive method that uses continuous optical topography to evaluate increases in oxygenated hemoglobin levels, an indicator of PFC activity that has been suggested to be associated with dyspnea [56-58]. The change in oxyhemoglobin and deoxyhemoglobin will be monitored using the Artinis fNIRS device (Artinis Medical Systems) [59], which will be secured over the participant’s forehead, with the center of each sensor pad vertically aligned with the iris. Light intensity data at 2 wavelengths (730 and 850 nm) will be obtained during CPET from the left and right sides of medial PFC and dorsolateral PFC using a cognitive optical brain imaging software at a sampling frequency of 4 Hz. Detector gain settings will be adjusted for light intensity, and filters will be applied to attenuate the physiological artifacts of respiration and pulse.

    Assessment Using PROMs
    Dyspnea

    The Medical Research Council (MRC) dyspnea scale [60], Borg dyspnea scale [54], and 18-item qualitative dyspnea descriptors will be used [61]. This will allow us to evaluate the quantitative and qualitative changes in respiratory symptoms.

    1. MRC dyspnea scale: the MRC dyspnea scale (1-5) will be used to assess the effect of breathlessness on daily activities at T0 [60]. It allows patients to indicate the extent to which breathlessness limits their daily functioning [60].
    2. Borg dyspnea scale: the highest score on a 10-point Borg scale at the beginning and end of CPET will be measured. The participants will also be asked to indicate their daily Borg dyspnea score before and after their IMT practice in their participant logs [62].
    3. Qualitative dyspnea descriptors: the qualitative dyspnea descriptors scale comprises a list of 18 dyspnea descriptors. Qualitative descriptors of dyspnea will be ascertained at T0 and at the end of CPET [61].
    Exercise Behaviors and Physical Activity

    Exercise behaviors will be measured using the 3-item Godin Leisure-Time Exercise Questionnaire—Leisure Score Index, which is a reliable and validated measure for this population [63]. This index assesses the frequency of mild, moderate, and strenuous bouts of leisure physical activity performed for at least 15 minutes over the past week. In addition, physical activity will be measured using a tracking device (Fitbit), which will record daily steps and active minutes for the study participants with hEDS or G-HSD [64,65].

    Measurement of HRQL

    The Short Form-36 Health Survey (version 1.0) will be used to assess generic HRQL [66]. It comprises 8 health domains that contribute to 2 physical and mental component scores (ranging from 0 to 100), with higher scores representing better HRQL. A 5-point change in the physical component scores or mental component scores is considered clinically significant [66].

    Depression, Anxiety, and Stress

    The Depression, Anxiety, and Stress scale has 21 items to assess mood (depression, anxiety, and stress) and has been administered to patients with hEDS [8]. It has acceptable to excellent internal consistency, and normative data are available [67].

    Anthropometric Measures

    Standard anthropometric measures will be captured for all the participants. Height, weight, waist circumference, and BMI information will be collected for the participants with hEDS or G-HSD from the electronic patient charts. The same measures will be collected for healthy controls during the T0 assessments.

    Clinical Assessments

    We will abstract standard GEAR program measures from the medical charts for all the participants with hEDS or G-HSD: 6-minute walk distance, lower extremity function (5-repetition sit-to-stand test), hand-grip strength, Bristol questionnaire, and Godin Leisure-Time Exercise scale. The Beighton score [68], Charlson comorbidity index [69], and medications such as opioids that can impact dyspnea will be abstracted from chart review.

    Sociodemographic Parameters

    We will abstract information on demographics such as age, ethnicity, sex, employment status, education level, and lifestyle factors (eg, smoking status) from the medical charts for the participants with hEDS or G-HSD. Demographic data will be collected from healthy controls via a demographic survey.

    Randomization

    After T0 assessments, the participants will be randomly allocated to the intervention or usual care group using a 1:1 ratio stratified by hEDS or G-HSD. The allocation of the participants to their groups will be randomized (blocks of 2 to 4) using shuffled, opaque envelopes by a biostatistician. The study participants and the research team and coordinator supervising the IMT will be aware of the group assignments.

    Study Arms

    Overview

    The participants in both the intervention and usual care groups will receive the standard-of-care rehabilitation in the GEAR program. Those in the intervention group will receive IMT in addition to the GEAR program components, as shown in Table 2.

    Table 2. Summary of the study procedures.
    Study groupsIMTa intervention group with participants with hEDSb or G-HSDc (n=17)Usual care group with participants with hEDS or G-HSD (n=17)
    Standard of care—GEARd program: baseline (T0), 4 weeks from T0 (T1), 8 weeks from T0 (T2), and 20 weeks from T0 (T3)
    • Aerobic, resistance, neuromuscular stabilization, and balance and proprioception exercises [36]
      • ‎
    • Aerobic, resistance, neuromuscular stabilization, and balance and proprioception exercises [36]
      • ‎
    Baseline assessment (details provided in Table 1)
    • Baseline assessment: explanation of equipment and tracking
      • ‎
    • IMT device POWERbreathe K5
      • ‎
    • IMT and exercise logs and Fitbit device and instructions
      • ‎
    • Fitbit device and instructions
      • ‎
    • Exercise logs
      • ‎
    • Baseline assessment:
      • Fitbit device and instructions
        • ‎
      • Exercise logs
        • ‎
      • ‎
    Study intervention: 8 weeks
    • 2 daily IMT sessions of 30 breaths (<5 minutes per session) for 5 days per week, up to 8 weeks
      • ‎
    • IMT starting at 20% of MIPe (up to a maximum of 60%)
      • ‎
    • Intensity progressed by 5% to 10% if the median weekly Borg dyspnea score is <7
      • ‎
    • Web-based supervision by the study team
      • ‎
    • Weekly check-in with the study coordinator
      • ‎
    • N/Af
      • ‎
    Follow-up: week 4 time point
    • Study assessments will be performed at week 4 from the home environment. Exercise logs and respiratory muscle endurance will be assessed
      • ‎
    • Study assessments will be performed at week 4 from the home environment. Exercise logs and respiratory muscle endurance will be assessed
      • ‎
    End point: week 8 time point
    • Study assessments conducted at baseline will be performed again at week 8 in the PFTg laboratory. Collection of logs, Fitbits, and IMT device (POWERbreathe K5) will be done at the end of the study
      • ‎
    • Study assessments conducted at baseline will be performed at week 8 in the PFT laboratory. Collection of logs, Fitbits, and IMT device (POWERbreathe K5) will be done at the end of the study.
      • ‎

    aIMT: inspiratory muscle training.

    bhEDS: hypermobile Ehlers-Danlos Syndrome.

    cG-HSD: generalized hypermobility spectrum disorder.

    dGEAR: GoodHope Exercise and Rehabilitation Program.

    eMIP: maximal inspiratory pressure.

    fN/A: not applicable.

    gPFT: pulmonary function test.

    Usual Care Group

    The standard-of-care rehabilitation in the GEAR program comprises 8 weeks of aerobic, resistance, neuromuscular stabilization, and balance and proprioception exercises performed in the home environment [1]. The participants in the GEAR program attend in-person or web-based exercise training sessions at the following intervals: T0, 4 weeks from T0, 8 weeks from T0, and 20 weeks from T0 to observe maintenance [46]. The GEAR program comprises three major elements: (1) an individualized home-based rehabilitation and exercise therapy, (2) education on the self-management of hEDS or G-HSD symptoms, and (3) a community resource engagement plan. These components are delivered by a team of physiotherapists and kinesiologists.

    Intervention Group (IMT)

    The participants in the intervention group will receive an individual and personalized prescription for an IMT program for 8 weeks. This IMT program will use the POWERbreathe K5 IMT device in the participants’ home environment combined with the standard-of-care rehabilitation as part of the GEAR program, as described earlier. A research coordinator will facilitate these training sessions and monitor the participants via the web for the first 3 sessions in the first week and once a week from weeks 2 to 8. Over 8 weeks, 2 daily IMT sessions of 30 breaths (<5 min/session) will be performed for 5 days per week, starting with 20% of the participants’ T0 MIP up to a maximum of 60%. This protocol was developed based on the previous literature on IMT applied in lung transplant candidates at our center [70-72]. The total workload per session (product of inspiratory muscle force and inhaled volume expressed in Joules) will be abstracted from the IMT device. Additional variables abstracted from the device will include inspiratory muscle load (cm H2O), mean power per breath (W), and mean volume per breath (Liters).

    The participants will be asked to record their resting and post-IMT Borg dyspnea scores for 5 days of the week (2 sessions per day), along with any side effects for each session. The median Borg dyspnea score for the previous week will be reviewed by the research coordinator, and IMT intensity will be increased by 5% to 10% of the T0 MIP if the median weekly Borg dyspnea score is <7 (very severe breathlessness with IMT) [54].

    The participants will be asked to maintain IMT diaries to assess adherence. They will receive instructions and feedback on how to optimize their home training efforts based on direct observation of their IMT with the POWERbreathe K5 device and review of IMT workload from the device. They will have the possibility to schedule additional sessions with the study team during the week, if further support is needed.

    Trial Outcomes

    Estimates of Intervention Feasibility

    Study feasibility will be assessed through recruitment rate, attrition, IMT program adherence, safety, and satisfaction (Textbox 1).

    Feasibility estimates.
    • Recruitment
      • We will evaluate the recruitment rate as the number of participants who consented and enrolled relative to the total number of eligible patients approached for eligibility assessment by the research coordinator. The reasons for nonparticipation in the study will be documented. A successful recruitment rate will be defined as 20% in this study.
    • Retention
      • Retention will be evaluated through participant attrition throughout the intervention period. For each arm of the study, the retention rate will be assessed by measuring the number of participants who completed all assessments compared with the number of participants who enrolled and randomized. A successful retention rate will be defined as ≥80% in this study.
    • Adherence
      • Adherence to inspiratory muscle training (IMT) in the intervention group will be tracked electronically and through participant logs (number of completed sessions of 30 breaths out of 10 planned sessions per week) with the IMT device over the 8-week period. Adherence will also be assessed during weekly communications with participants as well as through completed daily IMT logs, which will capture IMT training days and IMT prescription (percentage of maximal inspiratory pressure). These data will also be verified after the IMT device is returned. The number of completed IMT sessions will be reviewed from the recordings on the device.
      • The physical activity and exercise behaviors prescribed through the GoodHope Exercise and Rehabilitation Program will be monitored in both the intervention and usual care groups. Daily step counts will be assessed from the Fitbit device. The participants with hypermobile Ehlers-Danlos Syndrome or generalized hypermobility spectrum disorder will be asked to download the Fitbit app on their smartphones or tablets. A 1-page document highlighting the key steps for setting up the Fitbit tracker will be provided. We will also work with the participants via the web to set up the device if any problems arise. The exercise behaviors of the study participants in both groups will be reviewed using the self-reported exercise logs, which capture the exercise type, frequency, intensity, and duration on a daily basis. At the end of the baseline assessment, the study participants in both the usual care and intervention groups will be provided with documents explaining the maintenance and use of the study devices (eg, Fitbit, respiratory muscle endurance trainer, and IMT device for the intervention group).
    • Safety
      • The participants will log any adverse effects during the IMT program, which will be reviewed weekly by the research coordinator. Adverse effects are rare; however, symptoms previously observed during IMT include mild chest discomfort, worsening respiratory symptoms (eg, dyspnea), and possibly nausea related to hyperventilation [73]. The participants will also be strongly encouraged to immediately contact a member of the research team if they notice any adverse events. Study personnel will also inquire about chest discomfort or delayed-onset muscle soreness during IMT in weekly meetings to adjust IMT prescriptions and ensure tolerability of training intensity.
    • Satisfaction
      • Participation satisfaction and motivation to engage with the IMT program will be assessed in the intervention group using a standardized questionnaire administered at weeks 1, 4, and 8 after study enrollment.
    Textbox 1. Feasibility estimates.
    Primary Pilot Outcome

    The primary pilot outcome will be the change in MIP over the 8-week study period to demonstrate the efficacy of IMT, which has been shown to be an important physiological measure in several IMT studies [11,26,35,73].

    Secondary Outcomes

    The secondary outcome measures evaluated will include dyspnea, respiratory muscle structure and function, mood, and HRQL assessed at T0 and 8 weeks, as shown in Table 3.

    Table 3. Study outcomes.
    OutcomeAssessment measurementTime point
    Primary outcome

    		Respiratory muscle strengthMIPa (cm H2O)Baseline (T0) and 8 weeks (T2)
    Secondary outcomes

    		Pulmonary function


    		Spirometry and lung volumesFEV1b (L), FVCc (L), TLCd (L), RV/TLCe (%)Baseline (T0) and 8 weeks (T2)


    		OscillometryOscillometry: respiratory impedance, reactance, and resistanceBaseline (T0) and 8 weeks (T2)


    		Respiratory muscle endurance timeTime (seconds) using the Philips Threshold trainer at 30% of baseline MIPBaseline (T0), 4 weeks (T1), and 8 weeks (T2)


    		Diaphragm structure and functionDiaphragm thickness and thickening fractionBaseline (T0) and 8 weeks (T2)

    		PROMsf


    		DyspneaMRCg scale ratings, Borg dyspnea scale ratings, and Qualitative Dyspnea Scale ratingsBaseline (T0) and 8 weeks (T2)


    		Exercise and physical activity volumeGodin Leisure-Time Exercise Questionnaire scoresBaseline (T0) and 8 weeks (T2)


    		HRQLhSF-36i scoresBaseline (T0) and 8 weeks (T2)


    		Depression, anxiety, and stressDepression, Anxiety, and Stress scale scoresBaseline (T0) and 8 weeks (T2)

    		Cardiopulmonary exercise parameters


    		Aerobic and anaerobic capacityPeak aerobic capacity, anaerobic threshold, breathing reserve, and cycling power outputBaseline (T0) and 8 weeks (T2)


    		HRj response and chronotropic responseHR recovery (HR at 1 minute after CPETk – HR at the end of CPET) and chronotropic response index adjusted for age ([peak HR – resting HR × 100] / [220 – age] – [resting HR])Baseline (T0) and 8 weeks (T2)

    		Neural activity during exercise (prefrontal cortex)Oxyhemoglobin and total hemoglobin concentration changesBaseline (T0) and 8 weeks (T2)

    aMIP: maximal inspiratory pressure.

    bFEV1: forced expiratory volume in 1 second.

    cFVC: forced vital capacity.

    dTLC: total lung capacity.

    eRV/TLC: residual volume/total lung capacity ratio.

    fPROM: patient-reported outcome measure.

    gMRC: Medical Research Council.

    hHRQL: health-related quality of life.

    iSF-36: Short Form-36.

    jHR: heart rate.

    kCPET: cardiopulmonary exercise test.

    Statistical Analysis

    Proposed Data Analyses

    For objective 1, we aim to compare respiratory muscle structure and function and PROMs between patients with hEDS or G-HSD and healthy controls and to evaluate the main correlates with dyspnea in patients with hEDS or G-HSD. Descriptive statistics will be used for continuous variables (mean and SD or median and IQR), and frequencies will be used for categorical variables. We will use multivariable regression analysis to compare any differences between groups across respiratory parameters and PROMs, adjusted for EDS subtype (hEDS or G-HSD). We will explore the associations with peak Borg dyspnea scores during CPET using multivariable regression, with possible determinants being MIP, diaphragm thickening fraction, PFC activity, and PFT parameters.

    For objective 2, we aim to assess the feasibility of IMT and standard-of-care rehabilitation for improving respiratory muscle strength, exercise capacity, and PROMs compared with standard-of-care rehabilitation alone in patients with hEDS or G-HSD. Descriptive statistics will be used to summarize program adherence, recruitment, participant satisfaction, attrition, and safety in the hEDS or G-HSD study groups. Estimates of within- and between-group differences at T0, 4 weeks, and 8 weeks will be reported using means and 95% CI. Paired t tests and t tests will be used to compare the changes in the primary pilot outcome (MIP) and secondary measures over the 8-week study period within and between the 2 randomized groups.

    Sample Size
    Objective 1

    With the prevalence of dyspnea (MRC score: 2 out of 5) in 50% of the patients with hEDS and G-HSD, we estimate that 75% of the patients with hEDS will report a Borg dyspnea score of ≥4 (moderate dyspnea) compared with 25% of healthy controls after cardiopulmonary exercise, as previously observed at our center [74]. Thus, with a sample size of 34 patients with hEDS or G-HSD and 17 healthy controls, we will have 90% power to observe a significant difference in moderate dyspnea (α level=.05). Furthermore, given an estimate of 10 participants for each covariate in multivariable regression modeling, we reckon that enrollment of 34 participants with hEDS or G-HSD will allow us to explore at least 3 determinants of dyspnea in our models.

    Objective 2 (Primary Pilot Outcome)

    Given an estimated MIP comparable with that of moderate COPD patients (mean 51, SD 15 cm H2O), we anticipate a mean increase of 10 (SD 3.5) cm H2O in MIP in the IMT and exercise training group compared with the hEDS or G-HSD usual care group (exercise training alone; 5 cm H2O) [75]. Assuming a maximum attrition rate of 20% among the 34 RCT participants with hEDS or G-HSD, we will have 90% power (α=.05) to observe a significant difference in MIP with 17 participants per group.

    Data Management and Quality Assurance

    Our research team is trained in the measurement protocols and has expertise in performing physical assessments and PROMs in individuals with respiratory conditions. The research team has critically appraised the peer-review comments from the 2020 GoodHope Ehlers-Danlos Syndrome foundation grant (Multimedia Appendix 1) and has incorporated them into the study protocol. Most of the study assessments will be conducted at the PFT laboratory of Toronto General Hospital by experienced respiratory technicians. All equipment (ultrasound, fNIRS, and oscillometry) has been applied in the laboratory setting previously. In addition, our research team has expertise in conducting web-based assessments in the participants’ home environment, including IMT, given the COVID-19 environment.

    The research coordinator will guide the participants through each step of the study process. Standard operating procedures will be generated for each step related to data collection, data entry, and data handling. The research coordinator will ensure accuracy by periodically auditing the data in our research database. Although the research coordinator will attempt to have the participants complete the entirety of the assessments and questionnaires, if there are unanswered questions or missing data, the data will not be imputed, and analysis will be performed on the available data.

    The current institutional and national research ethics guidelines will be followed to ensure data privacy, security, and protection. Participant data will only be accessible by the research study team, and participants will be assigned a random participant ID, which will be linked to all the data. All the study data will be securely stored on a password-protected server. In the event of inappropriate data breaches, the following actions will be undertaken: (1) prevent further breach of information and attempt to retrieve breached information and (2) notify the institutional research ethics board immediately. Further action might be taken according to the recommendations from the research ethics board. Modifications to the study protocol will be approved by the research ethics board before implementation, communicated to funding agencies, and outlined in future publications.


    This research was funded in January 2021, and study enrollment began in August 2021 and will continue until December 2023. As of January 2023, a total of 4 participants with hEDS or G-HSD in the intervention group and 4 participants in the usual care group have completed the study, with 5 other participants with hEDS or G-HSD enrolled. A total of 11 healthy controls have completed the study. The results will be submitted for publication once data collection and assessments are complete.


    Summary

    This study will help characterize the multifactorial nature of dyspnea experienced by individuals with hEDS and G-HSD. Given the known impairments in respiratory muscle strength in this population, this study will allow us to assess the synergistic effects of IMT and standard-of-care rehabilitation on dyspnea, PROMs, and exercise capacity, which have not been previously characterized. The findings of this study will inform the feasibility of a larger study using IMT and standard-of-care rehabilitation that will be appropriately powered to assess the effects of IMT on PROMs and clinical outcomes. Furthermore, this study has the potential to inform our understanding of the mechanistic effects that IMT may have on diaphragm structure and function, lung physiology, and neurocognitive adaptations in this population.

    The literature describing respiratory manifestations in EDS and G-HSD has generally been limited to a few observational studies and case series involving mainly 4 subtypes: classical EDS, vascular EDS, hEDS, and G-HSD [2,9]. We chose to focus on the population with hEDS, as hEDS comprises the major subtype of EDS, and there is also a study highlighting respiratory muscle weakness and effectiveness of IMT [11]. The population with G-HSD was also chosen, as G-HSD is defined to be on the continuum of EDS and represents one of the most common diagnoses in our GEAR rehabilitation program, and the respiratory sequelae of G-HSD have not been well characterized [3]. Another important consideration factored into our selection of the EDS population was the risk of pneumothorax, which is generally lower in individuals with hEDS and G-HSD than in those with other subtypes. Thus, the inclusion of patients with hEDS and patients with G-HSD is owing to the representation of the majority (>90%) of the patients with EDS followed in our program.

    We hypothesize that IMT and standard-of-care rehabilitation will provide a positive synergistic effect on respiratory muscle function, PROMs, and clinical outcomes. IMT has been shown to improve dyspnea by increasing respiratory muscle strength [76]. In addition, aerobic and strength training has been shown to increase the strength of the respiratory and limb muscles and improve oxygen use, ventilatory efficiency, and exercise capacity [20,31]. Furthermore, IMT can have positive effects on dyspnea through neurocognitive adaptations [77]. Breathing exercises may induce motor-sensory neural adaptations in the diaphragmatic and respiratory muscles, which can improve dyspnea tolerance [77]. It is also postulated that improvements in exercise capacity and dyspnea levels through IMT may result in greater independence in daily activities and improved HRQL [78]. Despite the proposed beneficial effects of IMT, the ideal duration remains to be determined, with 8 weeks chosen for this study based on the recommendation that a duration of at least 6 weeks is required to derive respiratory muscle adaptations [79-81].

    Owing to the COVID-19 environment, a large proportion of research assessments and in-person care visits have transitioned to a web-based environment [82,83]. Patients often express concerns about the possibility of COVID-19 exposure and travel expenses for in-person assessments. Furthermore, the GEAR program has also adapted its format, with a proportion of web-based training sessions performed. Thus, we are closely monitoring enrollment numbers and if recruitment proves to be challenging because of the requirement for in-person visits, we will be able to amend the protocol to allow assessments to be performed via the web. In fact, most of the assessments in this study can be administered via the web, including all PROMs, respiratory muscle endurance testing, and IMT with electronic tracking on the device itself. The results of this study will demonstrate the potential of performing web-based IMT, especially with the emergence of tele-rehabilitation programs.

    Limitations

    This study has several limitations that need to be highlighted. First, our study focuses on hEDS and G-HSD, which represent most EDS disorders in our program. However, the findings may not be generalizable across less prevalent EDS subtypes (eg, classic EDS or vascular EDS). Second, all participants in this RCT will be enrolled in the GEAR program, and we anticipate that any differences in training volumes or physical activity levels will be negligible between the groups after randomization, but any differences over the 8-week IMT program will be explored. Third, we are unable to monitor adherence to the GEAR program in the intervention group. Moreover, IMT may not be suitable for all participants because of time restrictions, training preferences, and work-school schedules. However, the web-based environment provides participants with the flexibility to uptake the IMT program that best suits their schedules.

    Conclusions

    This study aims to provide a better understanding of the contributors to dyspnea in hEDS or G-HSD and highlight the association between dyspnea and respiratory muscle function, PROMs, and exercise capacity. The combination of IMT and standard-of-care rehabilitation training may provide a novel therapeutic strategy to improve respiratory muscle function and PROMs. A better understanding of the feasibility and efficacy of IMT and standard-of-care rehabilitation will provide insight into the use of IMT in the population with EDS and the population with G-HSD, given a shift toward tele-rehabilitation programs in the COVID-19 environment. This research will pave the way for future studies to evaluate respiratory management strategies in this population.

    Acknowledgments

    The research team would like to acknowledge the collaboration between the study participants and clinical staff at the University Health Network. This research is funded by the GoodHope Ehlers-Danlos Syndrome foundation at the University Health Network. DR receives research support from the Sandra Faire and Ivan Fecan Professorship in Rehabilitation Medicine. NAK receives financial research support from the Canadian Institute of Health Research Canada Graduate Scholarship–Master’s Program. The study sponsors had no role in the design of the study protocol and will have no involvement in the data collection process, data analysis, interpretation of the results, or manuscript preparation. This study is sponsored by the University Health Network.

    Data Availability

    The study data will be made available for review after trial completion and publication upon reasonable request from the corresponding author.

    Authors' Contributions

    DR conceived the study and participated in the design of the protocol and development of the intervention. DR, EG, LM, LL-H, WDR, CWC, CMR, DK, EH, KC, SR, DSM, and NM are the grant holders. SN coordinates the study under the direct supervision of DR. SN, ECP, and NAK are responsible for the implementation of the study. SN supervises the inspiratory muscle training home-based exercise program. DR and NAK helped draft this manuscript. ECP, SN, EG, LM, LL-H, WDR, CWC, CMR, DK, EH, KC, SR, SM, DSM, HC, and NM provided expert advice and reviewed the protocol. All the authors approved the final manuscript for submission.

    Conflicts of Interest

    None declared.

    ‎
    Multimedia Appendix 1

    Peer review report from the 2020 GoodHope Ehlers-Danlos Syndrome Foundation grant competition.

    PDF File (Adobe PDF File), 122 KB
    1. Mittal N, Mina DS, McGillis L, Weinrib A, Slepian PM, Rachinsky M, et al. The GoodHope Ehlers Danlos Syndrome Clinic: development and implementation of the first interdisciplinary program for multi-system issues in connective tissue disorders at the Toronto General Hospital. Orphanet J Rare Dis 2021 Aug 10;16(1):357 [FREE Full text] [CrossRef] [Medline]
    2. Chohan K, Mittal N, McGillis L, Lopez-Hernandez L, Camacho E, Rachinsky M, et al. A review of respiratory manifestations and their management in Ehlers-Danlos syndromes and hypermobility spectrum disorders. Chron Respir Dis 2021;18:14799731211025313 [FREE Full text] [CrossRef] [Medline]
    3. Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet 2017 Mar;175(1):8-26. [CrossRef] [Medline]
    4. Castori M, Camerota F, Celletti C, Grammatico P, Padua L. Quality of life in the classic and hypermobility types of Ehlers-Danlos syndrome [corrected]. Ann Neurol 2010 Jan;67(1):145-147. [CrossRef] [Medline]
    5. Castori M. Pain in Ehlers-Danlos syndromes: manifestations, therapeutic strategies and future perspectives. Expert Opin Orphan Drugs 2016 Sep 27;4(11):1145-1158. [CrossRef]
    6. Voermans NC, Knoop H, van de Kamp N, Hamel BC, Bleijenberg G, van Engelen BG. Fatigue is a frequent and clinically relevant problem in Ehlers-Danlos syndrome. Semin Arthritis Rheum 2010 Dec;40(3):267-274. [CrossRef] [Medline]
    7. Berglund B, Pettersson C, Pigg M, Kristiansson P. Self-reported quality of life, anxiety and depression in individuals with Ehlers-Danlos syndrome (EDS): a questionnaire study. BMC Musculoskelet Disord 2015 Apr 15;16:89 [FREE Full text] [CrossRef] [Medline]
    8. Krahe AM, Adams RD, Nicholson LL. Features that exacerbate fatigue severity in joint hypermobility syndrome/Ehlers-Danlos syndrome - hypermobility type. Disabil Rehabil 2018 Aug;40(17):1989-1996. [CrossRef] [Medline]
    9. Bascom R, Dhingra R, Francomano CA. Respiratory manifestations in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet 2021 Dec;187(4):533-548. [CrossRef] [Medline]
    10. Malfait F, Wenstrup RJ, De Paepe A. Clinical and genetic aspects of Ehlers-Danlos syndrome, classic type. Genet Med 2010 Oct;12(10):597-605 [FREE Full text] [CrossRef] [Medline]
    11. Reychler G, Liistro G, Piérard GE, Hermanns-Lê T, Manicourt D. Inspiratory muscle strength training improves lung function in patients with the hypermobile Ehlers-Danlos syndrome: a randomized controlled trial. Am J Med Genet A 2019 Mar;179(3):356-364. [CrossRef] [Medline]
    12. Morgan AW, Pearson SB, Davies S, Gooi HC, Bird HA. Asthma and airways collapse in two heritable disorders of connective tissue. Ann Rheum Dis 2007 Oct;66(10):1369-1373 [FREE Full text] [CrossRef] [Medline]
    13. Hakim AJ, Grahame R. Non-musculoskeletal symptoms in joint hypermobility syndrome. Indirect evidence for autonomic dysfunction? Rheumatology (Oxford) 2004 Sep;43(9):1194-1195. [CrossRef] [Medline]
    14. Ruiz Maya T, Fettig V, Mehta L, Gelb BD, Kontorovich AR. Dysautonomia in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders is associated with exercise intolerance and cardiac atrophy. Am J Med Genet A 2021 Dec;185(12):3754-3761 [FREE Full text] [CrossRef] [Medline]
    15. Kohn A, Chang C. The relationship between Hypermobile Ehlers-Danlos syndrome (hEDS), Postural Orthostatic Tachycardia syndrome (POTS), and Mast Cell Activation syndrome (MCAS). Clin Rev Allergy Immunol 2020 Jun;58(3):273-297. [CrossRef] [Medline]
    16. Benrud-Larson LM, Dewar MS, Sandroni P, Rummans TA, Haythornthwaite JA, Low PA. Quality of life in patients with postural tachycardia syndrome. Mayo Clin Proc 2002 Jun;77(6):531-537. [CrossRef] [Medline]
    17. Holtzhausen S, Unger M, Lupton-Smith A, Hanekom S. An investigation into the use of ultrasound as a surrogate measure of diaphragm function. Heart Lung 2018;47(4):418-424. [CrossRef] [Medline]
    18. Braun NM, Arora NS, Rochester DF. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 1983 Aug;38(8):616-623 [FREE Full text] [CrossRef] [Medline]
    19. Kreitzer SM, Saunders NA, Tyler HR, Ingram Jr RH. Respiratory muscle function in amyotrophic lateral sclerosis. Am Rev Respir Dis 1978 Mar;117(3):437-447. [CrossRef] [Medline]
    20. Saka S, Gurses HN, Bayram M. Effect of inspiratory muscle training on dyspnea-related kinesiophobia in chronic obstructive pulmonary disease: a randomized controlled trial. Complement Ther Clin Pract 2021 Aug;44:101418. [CrossRef] [Medline]
    21. Ayres JG, Pope FM, Reidy JF, Clark TJ. Abnormalities of the lungs and thoracic cage in the Ehlers-Danlos syndrome. Thorax 1985 Apr;40(4):300-305 [FREE Full text] [CrossRef] [Medline]
    22. Castori M, Camerota F, Celletti C, Grammatico P, Padua L. Ehlers-Danlos syndrome hypermobility type and the excess of affected females: possible mechanisms and perspectives. Am J Med Genet A 2010 Sep;152A(9):2406-2408. [CrossRef] [Medline]
    23. Shoemaker MJ, Donker S, LaPoe A. Systematic review: inspiratory muscle training in patients with chronic obstructive pulmonary disease: the state of the evidence. Cardiopulm Phys Ther J 2009 Sep;20(3):5-15. [CrossRef]
    24. Higashimoto Y, Honda N, Yamagata T, Matsuoka T, Maeda K, Satoh R, et al. Activation of the prefrontal cortex is associated with exertional dyspnea in chronic obstructive pulmonary disease. Respiration 2011;82(6):492-500 [FREE Full text] [CrossRef] [Medline]
    25. Herigstad M, Hayen A, Evans E, Hardinge FM, Davies RJ, Wiech K, et al. Dyspnea-related cues engage the prefrontal cortex: evidence from functional brain imaging in COPD. Chest 2015 Oct;148(4):953-961 [FREE Full text] [CrossRef] [Medline]
    26. Ram FS, Wellington SR, Barnes NC. Inspiratory muscle training for asthma. Cochrane Database Syst Rev 2003(4):CD003792. [CrossRef] [Medline]
    27. Basso-Vanelli RP, Di Lorenzo VA, Labadessa IG, Regueiro EM, Jamami M, Gomes EL, et al. Effects of inspiratory muscle training and calisthenics-and-breathing exercises in COPD with and without respiratory muscle weakness. Respir Care 2016 Jan;61(1):50-60 [FREE Full text] [CrossRef] [Medline]
    28. Sheel AW, Foster GE, Romer LM. Exercise and its impact on dyspnea. Curr Opin Pharmacol 2011 Jun;11(3):195-203. [CrossRef] [Medline]
    29. Sîrbu E. The effects of moderate aerobic training on cardiorespiratory parameters in healthy elderly subjects. J Phys Educ Sport 2012;12(4):560-563 [FREE Full text] [CrossRef]
    30. Zhang F, Zhong Y, Qin Z, Li X, Wang W. Effect of muscle training on dyspnea in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2021 Mar 05;100(9):e24930 [FREE Full text] [CrossRef] [Medline]
    31. Hanada M, Kasawara KT, Mathur S, Rozenberg D, Kozu R, Hassan SA, et al. Aerobic and breathing exercises improve dyspnea, exercise capacity and quality of life in idiopathic pulmonary fibrosis patients: systematic review and meta-analysis. J Thorac Dis 2020 Mar;12(3):1041-1055 [FREE Full text] [CrossRef] [Medline]
    32. Buryk-Iggers S, Mittal N, Santa Mina D, Adams SC, Englesakis M, Rachinsky M, et al. Exercise and rehabilitation in people with Ehlers-Danlos syndrome: a systematic review. Arch Rehabil Res Clin Transl 2022 Jun;4(2):100189 [FREE Full text] [CrossRef] [Medline]
    33. Weiner P, Azgad Y, Ganam R. Inspiratory muscle training combined with general exercise reconditioning in patients with COPD. Chest 1992 Nov;102(5):1351-1356. [CrossRef] [Medline]
    34. O'Brien K, Geddes EL, Reid WD, Brooks D, Crowe J. Inspiratory muscle training compared with other rehabilitation interventions in chronic obstructive pulmonary disease: a systematic review update. J Cardiopulm Rehabil Prev 2008;28(2):128-141. [CrossRef] [Medline]
    35. Koulopoulou M. Inspiratory muscle training in interstitial lung disease. Kingston University. 2015.   URL: https://eprints.kingston.ac.uk/id/eprint/35554/ [accessed 2022-12-01]
    36. Mittal N, Santa Mina D, Buryk-Iggers S, Lopez-Hernandez L, Hussey L, Franzese A, et al. The GoodHope Exercise and Rehabilitation (GEAR) program for people with Ehlers-Danlos syndromes and generalized hypermobility spectrum disorders. Front Rehabil Sci 2021 Nov 8;2:769792 [FREE Full text] [CrossRef] [Medline]
    37. Slade SC, Dionne CE, Underwood M, Buchbinder R. Consensus on exercise reporting template (CERT): explanation and elaboration statement. Br J Sports Med 2016 Dec;50(23):1428-1437. [CrossRef] [Medline]
    38. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Open Med 2010;4(1):e60-e68 [FREE Full text] [Medline]
    39. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013 Feb 05;158(3):200-207 [FREE Full text] [CrossRef] [Medline]
    40. American Thoracic Society, American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003 Jan 15;167(2):211-277. [CrossRef] [Medline]
    41. Oostveen E, MacLeod D, Lorino H, Farré R, Hantos Z, Desager K, ERS Task Force on Respiratory Impedance Measurements. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 2003 Dec;22(6):1026-1041 [FREE Full text] [CrossRef] [Medline]
    42. Cho E, Wu JK, Birriel DC, Matelski J, Nadj R, DeHaas E, et al. Airway oscillometry detects spirometric-silent episodes of acute cellular rejection. Am J Respir Crit Care Med 2020 Jun 15;201(12):1536-1544. [CrossRef] [Medline]
    43. Chang E, Vasileva A, Nohra C, Ryan CM, Chow CW, Yan Wu JK. Conducting respiratory oscillometry in an outpatient setting. J Vis Exp 2022 Apr 08(182):e63243. [CrossRef] [Medline]
    44. Al-Mutairi SS, Sharma PN, Al-Alawi A, Al-Deen JS. Impulse oscillometry: an alternative modality to the conventional pulmonary function test to categorise obstructive pulmonary disorders. Clin Exp Med 2007 Jun;7(2):56-64. [CrossRef] [Medline]
    45. Crim C, Celli B, Edwards LD, Wouters E, Coxson HO, Tal-Singer R, ECLIPSE investigators. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med 2011 Jul;105(7):1069-1078 [FREE Full text] [CrossRef] [Medline]
    46. Airwave Oscillometry Device | tremoflo® C-100. THORASYS.   URL: https://www.thorasys.com/solutions/tremoflo-c-100 [accessed 2022-12-15]
    47. Gutierrez C, Ghezzo RH, Abboud RT, Cosio MG, Dill JR, Martin RR, et al. Reference values of pulmonary function tests for Canadian Caucasians. Can Respir J 2004 Sep;11(6):414-424 [FREE Full text] [CrossRef] [Medline]
    48. Laveneziana P, Albuquerque A, Aliverti A, Babb T, Barreiro E, Dres M, et al. ERS statement on respiratory muscle testing at rest and during exercise. Eur Respir J 2019 Jun;53(6):1801214 [FREE Full text] [CrossRef] [Medline]
    49. Threshold IMT Breathing trainer. Philips Healthcare.   URL: https://www.usa.philips.com/healthcare/product/HCHS730010/treshold-inspiratory-muscle-trainer [accessed 2022-12-15]
    50. Goligher EC, Laghi F, Detsky ME, Farias P, Murray A, Brace D, et al. Measuring diaphragm thickness with ultrasound in mechanically ventilated patients: feasibility, reproducibility and validity. Intensive Care Med 2015 Apr;41(4):642-649. [CrossRef] [Medline]
    51. Martelli V, Mathur S, Wickerson L, Gottesman C, Helm D, Singer LG, et al. Impaired cardiac autonomic response in lung transplant patients: a retrospective cohort study. Clin Transplant 2019 Jul;33(7):e13612. [CrossRef] [Medline]
    52. Phan TT, Shivu GN, Abozguia K, Davies C, Nassimizadeh M, Jimenez D, et al. Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail 2010 Jan;3(1):29-34. [CrossRef] [Medline]
    53. Gupta M, Bansal V, Chhabra SK. Abnormal heart rate recovery and chronotropic incompetence on exercise in chronic obstructive pulmonary disease. Chron Respir Dis 2013 Aug;10(3):117-126 [FREE Full text] [CrossRef] [Medline]
    54. Kendrick KR, Baxi SC, Smith RM. Usefulness of the modified 0-10 Borg scale in assessing the degree of dyspnea in patients with COPD and asthma. J Emerg Nurs 2000 Jun;26(3):216-222. [CrossRef] [Medline]
    55. Borg E, Borg G, Larsson K, Letzter M, Sundblad BM. An index for breathlessness and leg fatigue. Scand J Med Sci Sports 2010 Aug;20(4):644-650. [CrossRef] [Medline]
    56. Miles M, Rodrigues A, Tajali S, Xiong Y, Orchanian-Cheff A, Reid WD, et al. Muscle and cerebral oxygenation during cycling in chronic obstructive pulmonary disease: a scoping review. Chron Respir Dis 2021;18:1479973121993494 [FREE Full text] [CrossRef] [Medline]
    57. Shadgan B, Reid WD, Gharakhanlou R, Stpublisher-ids L, Macnab AJ. Wireless near-infrared spectroscopy of skeletal muscle oxygenation and hemodynamics during exercise and ischemia. Spectroscopy 2009;23(5-6):233-241. [CrossRef]
    58. Herold F, Wiegel P, Scholkmann F, Müller NG. Applications of functional near-infrared spectroscopy (fNIRS) neuroimaging in exercise⁻cognition science: a systematic, methodology-focused review. J Clin Med 2018 Nov 22;7(12):466 [FREE Full text] [CrossRef] [Medline]
    59. NIRS and fNIRS devices. Artinis Medical Systems.   URL: https://www.artinis.com/nirs-devices [accessed 2022-12-15]
    60. Munari AB, Gulart AA, Dos Santos K, Venâncio RS, Karloh M, Mayer AF. Modified Medical Research Council Dyspnea Scale in GOLD classification better reflects physical activities of daily living. Respir Care 2018 Jan;63(1):77-85 [FREE Full text] [CrossRef] [Medline]
    61. Laveneziana P. Qualitative aspects of exertional dyspnea in patients with restrictive lung disease. Multidiscip Respir Med 2010 Jun 30;5(3):211-215 [FREE Full text] [CrossRef] [Medline]
    62. Borg G. Psychophysical scaling with applications in physical work and the perception of exertion. Scand J Work Environ Health 1990;16 Suppl 1:55-58 [FREE Full text] [CrossRef] [Medline]
    63. Godin G, Jobin J, Bouillon J. Assessment of leisure time exercise behavior by self-report: a concurrent validity study. Can J Public Health 1986;77(5):359-362. [Medline]
    64. Fitbit Inc Store.   URL: https://www.fitbit.com/store%23one [accessed 2022-12-01]
    65. Hamari L, Kullberg T, Ruohonen J, Heinonen OJ, Díaz-Rodríguez N, Lilius J, et al. Physical activity among children: objective measurements using Fitbit One® and ActiGraph. BMC Res Notes 2017 Apr 20;10(1):161 [FREE Full text] [CrossRef] [Medline]
    66. McHorney CA, Ware Jr JE, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993 Mar;31(3):247-263. [CrossRef] [Medline]
    67. Osman A, Wong JL, Bagge CL, Freedenthal S, Gutierrez PM, Lozano G. The Depression Anxiety Stress Scales-21 (DASS-21): further examination of dimensions, scale reliability, and correlates. J Clin Psychol 2012 Dec;68(12):1322-1338. [CrossRef] [Medline]
    68. Malek S, Reinhold EJ, Pearce GS. The Beighton Score as a measure of generalised joint hypermobility. Rheumatol Int 2021 Oct;41(10):1707-1716 [FREE Full text] [CrossRef] [Medline]
    69. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373-383. [CrossRef] [Medline]
    70. Charususin N, Gosselink R, Decramer M, McConnell A, Saey D, Maltais F, et al. Inspiratory muscle training protocol for patients with chronic obstructive pulmonary disease (IMTCO study): a multicentre randomised controlled trial. BMJ Open 2013 Aug 05;3(8):e003101 [FREE Full text] [CrossRef] [Medline]
    71. Wu W, Guan L, Zhang X, Li X, Yang Y, Guo B, et al. Effects of two types of equal-intensity inspiratory muscle training in stable patients with chronic obstructive pulmonary disease: a randomised controlled trial. Respir Med 2017 Nov;132:84-91 [FREE Full text] [CrossRef] [Medline]
    72. Rozenberg D, Coiffard B, Granton JT, Schreiber AF, Wong J, Fard S, et al. Feasibility of pre-operative inspiratory muscle training in lung transplant candidates with interstitial lung disease. Am J Respir Crit Care Med 2021;203:A4136. [CrossRef]
    73. Souza H, Rocha T, Pessoa M, Rattes C, Brandão D, Fregonezi G, et al. Effects of inspiratory muscle training in elderly women on respiratory muscle strength, diaphragm thickness and mobility. J Gerontol A Biol Sci Med Sci 2014 Dec;69(12):1545-1553. [CrossRef] [Medline]
    74. Greutmann M, Rozenberg D, Le TL, Silversides CK, Granton JT. Recovery of respiratory gas exchange after exercise in adults with congenital heart disease. Int J Cardiol 2014 Sep 20;176(2):333-339. [CrossRef] [Medline]
    75. Charususin N, Gosselink R, Decramer M, Demeyer H, McConnell A, Saey D, et al. Randomised controlled trial of adjunctive inspiratory muscle training for patients with COPD. Thorax 2018 Oct;73(10):942-950. [CrossRef] [Medline]
    76. Petrovic M, Reiter M, Zipko H, Pohl W, Wanke T. Effects of inspiratory muscle training on dynamic hyperinflation in patients with COPD. Int J Chron Obstruct Pulmon Dis 2012;7:797-805 [FREE Full text] [CrossRef] [Medline]
    77. Norweg A, Collins EG. Evidence for cognitive-behavioral strategies improving dyspnea and related distress in COPD. Int J Chron Obstruct Pulmon Dis 2013;8:439-451 [FREE Full text] [CrossRef] [Medline]
    78. Geddes EL, Reid WD, Crowe J, O'Brien K, Brooks D. Inspiratory muscle training in adults with chronic obstructive pulmonary disease: a systematic review. Respir Med 2005 Nov;99(11):1440-1458 [FREE Full text] [CrossRef] [Medline]
    79. Lee AL, Holland AE. Time to adapt exercise training regimens in pulmonary rehabilitation--a review of the literature. Int J Chron Obstruct Pulmon Dis 2014 Nov 10;9:1275-1288 [FREE Full text] [CrossRef] [Medline]
    80. Tzelepis G, Kasas V, McCool FD. Inspiratory muscle adaptations following pressure or flow training in humans. Eur J Appl Physiol Occup Physiol 1999 May;79(6):467-471. [CrossRef] [Medline]
    81. Shei RJ. Recent advancements in our understanding of the ergogenic effect of respiratory muscle training in healthy humans: a systematic review. J Strength Cond Res 2018 Sep;32(9):2665-2676 [FREE Full text] [CrossRef] [Medline]
    82. Werneke MW, Deutscher D, Grigsby D, Tucker CA, Mioduski JE, Hayes D. Telerehabilitation during the COVID-19 pandemic in outpatient rehabilitation settings: a descriptive study. Phys Ther 2021 Jul 01;101(7):pzab110 [FREE Full text] [CrossRef] [Medline]
    83. Dixit S, Borghi-Silva A, Bairapareddy KC. Revisiting pulmonary rehabilitation during COVID-19 pandemic: a narrative review. Rev Cardiovasc Med 2021 Jun 30;22(2):315-327 [FREE Full text] [CrossRef] [Medline]

    ‎
    CONSORT: Consolidated Standards of Reporting Trials
    COPD: chronic obstructive pulmonary disease
    CPET: cardiopulmonary exercise test
    EDS: Ehlers-Danlos Syndrome
    fNIRS: functional near-infrared spectroscopy
    GEAR: GoodHope Exercise and Rehabilitation Program
    G-HSD: generalized hypermobility spectrum disorder
    hEDS: hypermobile Ehlers-Danlos Syndrome
    HR: heart rate
    HRQL: health-related quality of life
    IMT: inspiratory muscle training
    MIP: maximal inspiratory pressure
    MRC: Medical Research Council
    PFC: prefrontal cortex
    PFT: pulmonary function test
    PROM: patient-reported outcome measure
    RCT: randomized controlled trial
    T0: baseline

    Edited by T Leung; This paper was peer reviewed by the 2020 GoodHope Ehlers-Danlos Syndrome Foundation grant competitition - Krembil Research Institute (Toronto, Ontario, Canada). See the Multimedia Appendix for the peer-review report; submitted 17.12.22; accepted 31.01.23; published 20.03.23

    Copyright

    ©Dmitry Rozenberg, Noor Al Kaabi, Encarna Camacho Perez, Sahar Nourouzpour, Laura Lopez-Hernandez, Laura McGillis, Ewan Goligher, W Darlene Reid, Chung-Wai Chow, Clodagh M Ryan, Dinesh Kumbhare, Ella Huszti, Kateri Champagne, Satish Raj, Susanna Mak, Daniel Santa Mina, Hance Clarke, Nimish Mittal. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 20.03.2023.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included.